Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Director Mark A. Kronenfeld bought 1,000 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was acquired at an average cost of $41.60 per share, with a total value of $41,600.00. Following the completion of the transaction, the director now directly owns 6,795 shares of the company’s stock, valued at $282,672. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) traded up $1.90 during trading hours on Monday, reaching $42.05. 787,300 shares of the company traded hands, compared to its average volume of 929,271. Pacira Pharmaceuticals, Inc. has a 1 year low of $29.81 and a 1 year high of $58.95. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. The firm had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.20 EPS. analysts forecast that Pacira Pharmaceuticals, Inc. will post -0.96 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/11/13/pacira-pharmaceuticals-inc-pcrx-director-buys-41600-00-in-stock.html.

Several research firms have commented on PCRX. BMO Capital Markets decreased their target price on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a “market perform” rating for the company in a research report on Thursday, August 3rd. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Thursday. Canaccord Genuity reissued a “buy” rating and issued a $56.00 target price on shares of Pacira Pharmaceuticals in a research report on Monday, July 31st. ValuEngine downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, HC Wainwright set a $59.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. Pacira Pharmaceuticals has an average rating of “Hold” and a consensus price target of $49.71.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Pacira Pharmaceuticals by 9.2% during the 2nd quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock valued at $165,914,000 after purchasing an additional 294,494 shares during the last quarter. Vanguard Group Inc. raised its stake in Pacira Pharmaceuticals by 7.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock valued at $146,538,000 after purchasing an additional 211,982 shares during the last quarter. HealthCor Management L.P. raised its stake in Pacira Pharmaceuticals by 63.1% during the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock valued at $85,564,000 after purchasing an additional 693,799 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in Pacira Pharmaceuticals by 5.3% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,285,850 shares of the company’s stock valued at $48,284,000 after purchasing an additional 64,510 shares during the last quarter. Finally, Macquarie Group Ltd. raised its stake in Pacira Pharmaceuticals by 5.8% during the 3rd quarter. Macquarie Group Ltd. now owns 1,154,545 shares of the company’s stock valued at $43,353,000 after purchasing an additional 63,015 shares during the last quarter. Hedge funds and other institutional investors own 99.64% of the company’s stock.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.